Cover Image

A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications

The treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) by targeting Prostate Specific Membrane Antigen (PSMA), that is ubiquitously expressed on malicious cells, using177Lu-PSMA-617, has been showing great potential. Considering the promising results from Radioligand Therapy (RLT)...

Full description

Saved in:

Bibliographic Details
Main Authors:	K.S. Ajish Kumar (Author), Anupam Mathur (Author)
Format:	Book
Published:	Elsevier, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Total chemical synthesis of PSMA-11: API for 68Ga-PSMA-11 used for prostate cancer diagnosis
by: K.S. Ajish Kumar, et al.
Published: (2021)

177Lu-PSMA-617 for metastatic prostate cancer in India
by: Aruni Ghose, et al.
Published: (2024)

Expression of Prostate-Specific Membrane Antigen (PSMA) in Brain Glioma and its Correlation with Tumor Grade
by: Hiva Saffar, et al.
Published: (2018)

Differences in Distribution and Detection Rate of the [<sup>68</sup>Ga]Ga-PSMA Ligands PSMA-617, -I&T and -11-Inter-Individual Comparison in Patients with Biochemical Relapse of Prostate Cancer
by: Falk Gühne, et al.
Published: (2021)

Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake
by: Falguni Basuli, et al.
Published: (2022)

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues
by: Jean-Philippe Sinnes, et al.
Published: (2020)

An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer
by: Ya'nan Ren, et al.
Published: (2022)

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
by: Ann-Christin Eder, et al.
Published: (2022)

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer
by: Niranjan Meher, et al.
Published: (2023)

A Preclinical Study of an <sup>125</sup>I-Labeled PSMA Ligand for Prostate-Cancer Puncture
by: Xiaohui Luan, et al.
Published: (2022)

Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patients
by: Hinke Siebinga, et al.
Published: (2023)

Lutetium-177-Labeled Prostate-Specific Membrane Antigen-617 for Molecular Imaging and Targeted Radioligand Therapy of Prostate Cancer
by: Rien Ritawidya, et al.
Published: (2023)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
by: Fanny Lundmark, et al.
Published: (2020)

[<sup>177</sup>Lu]Lu-PSMA-617 (Pluvicto<sup>TM</sup>): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2022)

FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer
by: Asim Kichloo MD, et al.
Published: (2020)

Optimized Therapeutic <sup>177</sup>Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022)

Human ABC and SLC Transporters: The Culprit Responsible for Unspecific PSMA-617 Uptake?
by: Harun Taş, et al.
Published: (2024)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2019)

Advances in <sup>177</sup>Lu-PSMA and <sup>225</sup>Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Sui Wai Ling, et al.
Published: (2022)

Up-Regulation of PSMA Expression In Vitro as Potential Application in Prostate Cancer Therapy
by: Roswitha Runge, et al.
Published: (2023)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
by: Veronika Barbara Felber, et al.
Published: (2021)

Efficacy and Safety of [<sup>225</sup>Ac]Ac-PSMA-617 Augmented [<sup>177</sup>Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
by: Florian Rosar, et al.
Published: (2021)

<sup>64</sup>Cu-DOTHA<sub>2</sub>-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window
by: Marie-Christine Milot, et al.
Published: (2022)

RadioLigand Therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
by: Marie Terroir, et al.
Published: (2023)

Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer
by: Erika Murce, et al.
Published: (2023)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024)

Characterization of Non-Specific Uptake and Retention Mechanisms of [<sup>177</sup>Lu]Lu-PSMA-617 in the Salivary Glands
by: Nathalie Heynickx, et al.
Published: (2023)

Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617
by: Amanda Kristiansson, et al.
Published: (2022)

Theranostic Potential of the iPSMA-Bombesin Radioligand in Patients with Metastatic Prostate Cancer: A Pilot Study
by: Sofía González-Rueda, et al.
Published: (2024)

PMP(Porphyrin-Micelle-PSMA) Nanoparticles for Photoacoustic and Ultrasound Signal Amplification in Mouse Prostate Cancer Xenografts
by: Daehyun Kim, et al.
Published: (2021)

Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov
by: Claus Zippel, et al.
Published: (2020)

Optimized <sup>68</sup>Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022)

Standardization of the [<sup>68</sup>Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer
by: Leonardo L. Fuscaldi, et al.
Published: (2021)

Synthesis of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
by: Javier Giglio, et al.
Published: (2018)

Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow)
by: Else A. Aalbersberg, et al.
Published: (2020)

Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands
by: Fanny Lundmark, et al.
Published: (2022)

[<sup>177</sup>Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative <i>In Vitro</i> Autoradiography
by: Roswitha Tönnesmann, et al.
Published: (2019)

Glu-Urea-Lys Scaffold Functionalized Superparamagnetic Iron Oxide Nanoparticles Targeting PSMA for In Vivo Molecular MRI of Prostate Cancer
by: Wei Zhou, et al.
Published: (2022)

Imageological/Structural Study regarding the Improved Pharmacokinetics by <sup>68</sup>Ga-Labeled PEGylated PSMA Multimer in Prostate Cancer
by: Huihui Zhang, et al.
Published: (2023)

Different PSMA Radiopharmaceuticals: A Comparative Study of [<sup>18</sup>F]F-PSMA-1007, [<sup>18</sup>F]F-JK-PSMA-7, and [<sup>99m</sup>Tc]Tc-PSMA-I&S in the Skeletal System
by: Zsófia Sára Mikó, et al.
Published: (2024)